No label defined (Q3071752)

From EU Knowledge Graph
Revision as of 12:31, 16 August 2021 by DG Regio (talk | contribs) (‎Created claim: summary (P836): Icosagen Cell Factory OÜ commercialises patented technologies through the development and production of antibodies to diagnostic and pharmaceutical companies. In the chosen business model, personal communication with customers not only influences the technological performance of the sales results. The main means of developing a relationship network in the US drug development market, and thereby promoting export sales of the service, is to presen...)
Jump to navigation Jump to search
Project Q3071752 in Estonia
Language Label Description Also known as
English
No label defined
Project Q3071752 in Estonia

    Statements

    0 references
    32,943.00 Euro
    0 references
    57,559.0 Euro
    0 references
    57.23 percent
    0 references
    1 May 2019
    0 references
    28 February 2022
    0 references
    Icosagen Cell Factory OÜ
    0 references

    58°22'0.84"N, 26°39'47.41"E
    0 references
    61713
    0 references
    Icosagen Cell Factory OÜ kommertsialiseerib patenteeritud tehnoloogiaid läbi antikehade arendamise ja tootmise teenuse osutamise diagnostika- ja farmaatsiaettevõtetele. Valitud ärimudeli puhul mõjutab müügitulemusi tehnoloogilisele võimekusele lisaks ka isiklik suhtlus klientidega. USA ravimiarenduse turul suhtevõrgustiku arendamise ja seeläbi teenuse eksportmüügi edendamise peamiseks vahendiks on ettevõtte esitlemine suurimatel USA ravimiarenduse messidel ja konverentsidel. (Estonian)
    0 references
    Icosagen Cell Factory OÜ commercialises patented technologies through the development and production of antibodies to diagnostic and pharmaceutical companies. In the chosen business model, personal communication with customers not only influences the technological performance of the sales results. The main means of developing a relationship network in the US drug development market, and thereby promoting export sales of the service, is to present the company at the largest US drug development fairs and conferences. (English)
    16 August 2021
    0 references

    Identifiers

    2014-2020.5.01.19-1075
    0 references